Regencell Bioscience Holdings (RGC) Financials
$6.89
As on 04-Sep-2026 16:18EDT
Market cap
$2,720 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2230.4
Div. Yield
0 %
Cashflow ($ Mln) |
Jun-25 | Jun-24 | Jun-23 | Jun-22 | Jun-21 | Jun-20 | Jun-19 | Jun-18 | Jun-17 | Jun-16 | Jun-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-3.11
|
-4.00
|
-4.96
|
-5.27
|
-0.77
|
-0.73
|
|||||
|
Cash Flow from Investing Activities
|
2.69
|
5.24
|
0.06
|
-10.78
|
-10.78
|
-0.12
|
|||||
|
Cash from Financing Activities
|
--
|
0.10
|
0.13
|
22.41
|
0.44
|
0.99
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
--
|
Financials Ratios |
Jun-25 | Jun-24 | Jun-23 | Jun-22 | Jun-21 | Jun-20 | Jun-19 | Jun-18 | Jun-17 | Jun-16 | Jun-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-0.01
|
-0.01
|
-0.01
|
-0.02
|
0.00
|
0.00
|
|||||
|
Cash EPS ($)
|
-0.01
|
-0.01
|
-0.01
|
-0.01
|
0.00
|
0.00
|
|||||
|
Adjusted Book Value ($)
|
0.01
|
0.02
|
0.02
|
0.03
|
--
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
-0.01
|
-0.01
|
-0.01
|
-0.01
|
0.00
|
0.00
|
|||||
|
Free Cash Flow per Share ($)
|
-0.01
|
-0.01
|
-0.01
|
-0.01
|
0.00
|
0.00
|
Profitability Ratios |
Jun-25 | Jun-24 | Jun-23 | Jun-22 | Jun-21 | Jun-20 | Jun-19 | Jun-18 | Jun-17 | Jun-16 | Jun-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
-52.29
|
-41.37
|
-38.71
|
-84.73
|
-2,606.18
|
-245.31
|
|||||
|
ROE (%)
|
-54.81
|
-42.49
|
-40.36
|
-113.60
|
40.51
|
36.19
|
|||||
|
ROA (%)
|
-50.50
|
-40.85
|
-38.32
|
-80.86
|
-315.34
|
-214.54
|
|||||
|
EBIT Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Net Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
Jun-25 | Jun-24 | Jun-23 | Jun-22 | Jun-21 | Jun-20 | Jun-19 | Jun-18 | Jun-17 | Jun-16 | Jun-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EBIT Growth (%)
|
17.85
|
28.03
|
20.18
|
-449.79
|
-70.04
|
-107.77
|
|||||
|
Net Profit Growth (%)
|
16.68
|
26.73
|
20.90
|
-451.16
|
-65.78
|
-107.77
|
|||||
|
EPS Growth (%)
|
0.17
|
0.27
|
0.21
|
-3.24
|
-0.66
|
-31.39
|
|||||
|
Book Value Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
Jun-25 | Jun-24 | Jun-23 | Jun-22 | Jun-21 | Jun-20 | Jun-19 | Jun-18 | Jun-17 | Jun-16 | Jun-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
-2,350.85
|
-386.21
|
-1,940.52
|
-2,305.32
|
--
|
--
|
|||||
|
Price / Book Value
|
1,733.64
|
202.15
|
947.02
|
1,002.71
|
--
|
--
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-2,638.78
|
-457.08
|
-2,150.52
|
-2,445.75
|
--
|
--
|
|||||
|
Close Price ($)
|
17.04
|
0.09
|
0.61
|
0.91
|
--
|
--
|
|||||
|
High Price ($)
|
83.60
|
0.61
|
1.14
|
1.55
|
--
|
--
|
|||||
|
Low Price ($)
|
0.08
|
--
|
0.56
|
0.16
|
--
|
--
|
|||||
|
Market Cap ($ Cr)
|
--
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
Jun-25 | Jun-24 | Jun-23 | Jun-22 | Jun-21 | Jun-20 | Jun-19 | Jun-18 | Jun-17 | Jun-16 | Jun-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
0.11
|
0.01
|
0.04
|
0.05
|
-0.92
|
-1.16
|
|||||
|
Short term debt to equity ratio
|
0.06
|
0.01
|
0.04
|
0.02
|
-0.92
|
-1.16
|
|||||
|
Current Ratio
|
7.39
|
41.92
|
19.15
|
28.46
|
0.02
|
0.12
|
|||||
|
Quick Ratio
|
--
|
42.71
|
19.24
|
28.51
|
0.02
|
--
|
|||||
|
Interest Coverage
|
--
|
--
|
--
|
-327.14
|
--
|
--
|
Operating Efficiency Ratios |
Jun-25 | Jun-24 | Jun-23 | Jun-22 | Jun-21 | Jun-20 | Jun-19 | Jun-18 | Jun-17 | Jun-16 | Jun-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Asset Turnover
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Inventory Days
|
-142.08
|
-51.27
|
-19.97
|
-10.59
|
-102.66
|
--
|
|||||
|
Payable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|